Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC, Japp AG, Prasad SK, Semple S, Newby DE, Dweck MR. · 2017
Read Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis. by Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC, Japp AG, Prasad SK, Semple S, Newby DE, Dweck MR. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5683736.txt.
Introduction
Chin and co-authors report a cohort study in JACC: Cardiovascular Imaging. It links heart muscle scarring with decline in aortic stenosis. Scarring drives the shift from thickened muscle to heart failure. Magnetic resonance scans can map two kinds of fibrosis. T1 mapping shows diffuse scarring as expanded tissue space. Late enhancement imaging marks replacement scar directly. The study enrolled 203 subjects prospectively. Of these, 166 had aortic stenosis and 37 were healthy.
Patients split into three scan-based groups. Half had normal myocardium on imaging. About a fifth showed expanded tissue space only. The rest had clear replacement scar. Worse scarring tracked with more injury and weaker function. Death rates rose stepwise across the groups.
Catalog record
| CREATOR | Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, Jenkins W, Koo M, Mirsadraee S, White AC, Japp AG, Prasad SK, Semple S, Newby DE, Dweck MR. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis By Calvin WL Chin, Russell J Everett, Jacek Kwiecinski, Alex T Vesey, Emily Yeung, Gavin Esson, William Jenkins, Maria Koo, Saeed Mirsadraee, Audrey C White, Alan G Japp, Sanjay K Prasad Published in: Jacc. Cardiovascular Imaging DOI: 10.1016/j.jcmg.2016.10.007 ABSTRACT Abstract Objectives Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. Background Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis. Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis. Methods In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male]; 37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m2) was used to define extracellular compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined during 2.9 ± 0.8 years of follow up. Results iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r = 0.87; p < 0.001; n = 11) and was increased in patients with aortic stenosis (23.6 ± 7.2 ml/m2 vs. 16.1 ± 3.2 ml/m2 in control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium (iECV <22.5 ml/m2; 51% of patients), extracellular expansion (iECV ≥22.5 ml/m2; 22%), and replacement fibrosis (presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years, respectively; p = 0.009). Conclusions CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis; NCT01755936) Key Words: aortic stenosis, fibrosis, hypertrophy, magnetic resonance imaging, myocardium, T1 mapping Abbreviations and Acronyms: AVR, aortic valve replacement; BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; cTnI, cardiac troponin I; ECV, extracellular volume; ECG, electrocardiogram; iECV, indexed extracellular volume; IQR, interquartile range; LGE, late gadolinium enhancement; LV, left ventricular; LVH, left ventricular hypertrophy Calcific aortic stenosis is the most common valvular heart condition in the western world and a major public health burden (1). In recent years, the role of left ventricular (LV) remodeling in disease progression, symptom development, and adverse cardiovascular events in aortic stenosis has been increasingly appreciated (2). In the initial phases, the increased afterload imposed by aortic valve narrowing induces adaptive left ventricular hypertrophy (LVH) that acts to maintain wall stress and cardiac output. Ultimately, this process decompensates, and patients transition from hypertrophy to heart failure and the development of symptoms and adverse cardiovascular events 2, 3. This transition often correlates poorly with the severity of aortic valve narrowing and is predominantly driven by myocardial fibrosis and myocyte cell death (4), which is perhaps a consequence of supply–demand mismatch and myocardial ischemia in the hypertrophied myocardium (2). Therefore, there is considerable interest in developing novel biomarkers to detect the early signs of LV decompensation. Cardiac magnetic resonance imaging (CMR) provides the noninvasive gold standard method for measuring LV wall thickness, mass, volumes, and ejection fraction. Moreover, it is able to detect structural changes in the LV myocardium, including replacement fibrosis with the late gadolinium technique and expansion of the extracellular volume using T1 mapping (5). The latter in part reflects increases in diffuse myocardial fibrosis (a reversible early form of fibrosis) (6) and potential changes in the intravascular compartment. Early studies have suggested that CMR-derived measures of LV mass and replacement myocardial fibrosis are of prognostic significance 7, 8. However, these studies have largely been conducted in small cohorts of patients with end-stage aortic stenosis who were referred to CMR on clinical grounds. Therefore, these findings may have been confounded by referral bias, which limited their applicability and generalizability to the broad population of patients with aortic stenosis. Moreover, comparisons with age- and sex-matched control populations and prognostic T1 mapping studies have been lacking. We report the largest prospective study to evaluate systematically the usefulness of CMR in patients with aortic stenosis. In particular, we investigated its ability to detect expansion of extracellular volume (ECV) and replacement myocardial fibrosis, and how these are related to other markers of LV decompensation, functional capacity, and clinical outcomes. METHODS Study population All stable patients with at least mild aortic stenosis (aortic jet velocity ≥2 m/s) who attended the Edinburgh Heart Centre between March 2012 and August 2014 were invited to participate in this prospective observational cohort study. The exclusion criteria were other forms of valvular heart disease (≥ moderate severity), significant co-morbidities with limited life expectancy, contraindications to gadolinium-enhanced CMR, and acquired or inherited nonischemic cardiomyopathies (as assessed by clinical history or ultimately by CMR). In addition, we recruited healthy volunteers from the community with similar demographic characteristics in terms of age and sex, but no history or clinical features consistent with current cardiovascular disease. The study was conducted in accordance with the Declaration of Helsinki and approved by the local research committee. Written informed consent was obtained from all participants. Subject characterization All subjects underwent detailed clinical evaluation including history, physical examination, and electrocardiography. In addition, venous blood samples were obtained for evaluation of biochemistry and cardiac biomarkers of interest. Cardiac biomarkers Plasma cardiac troponin I (cTnI) concentrations were determined by the ARCHITECT STAT high-sensitivity cTnI assay (Abbot Laboratories, Abbott Park, Illinois) (9). The brain natriuretic peptide (BNP) concentration was determined with Triage BNP assay (Biosite Inc., San Diego, California). 6-min walk test A 6-min walk test was performed in 156 (94%) patients as an objective measure of functional capacity in our predominantly older adult cohort, many of whom could not perform an exercise tolerance test. Explicit instructions were given to patients asking them to walk as far as possible for 6 min. Echocardiography Comprehensive transthoracic echocardiography was performed in all patients (iE33, Philips Medical Systems, the Netherlands) by a dedicated research ultrasonographer (A.C.W.) and a cardiologist certified in echocardiography (C.W.L.C.). The severity of aortic stenosis and diastolic function were assessed according to American Society of Echocardiography (ASE) guidelines (Online Appendix). Cardiac magnetic resonance CMR was performed using a 3-T scanner (MAGNETOM Verio, Siemens AG, Erlangen, Germany). Short-axis cine images were acquired and used to calculate ventricular volumes, mass, and function. Left ventricular hypertrophy (LVH) was defined as LV mass (indexed to body surface area using the Du Bois formula) >95th percentile using age- and sex-specific reference ranges (10). LV longitudinal function was determined by measuring the difference in mitral annular displacement between end-systole and end-diastole (Online Appendix). Focal replacement fibrosis and ECV expansion were assessed in